Learn the important Racket concepts with practical examples, from functions and recursion to macros, contracts, streams, and ...

Learning to program in C on an online platform can provide structured learning and a certification to show along with your resume. Learning C can still be useful in 2026, especially if you want to ...

Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Abstract: Bayesian inference provides a methodology for parameter estimation and uncertainty quantification in machine learning and deep learning methods. Variational inference and Markov Chain ...

Send a note to Doug Wintemute, Kara Coleman Fields and our other editors. We read every email. By submitting this form, you agree to allow us to collect, store, and potentially publish your provided ...

One reason Recursion Pharmaceuticals could become a big deal is that its goal is to usher a paradigm shift into the pharmaceutical industry. Even with impressive technological progress over the past ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals uses AI to improve the process of discovering and developing drugs, making it easier and more cost-effective. Most medicines that enter clinical trials never reach the market ...

“Of all ideas I have introduced to children, recursion stands out as the one idea that is particularly able to evoke an excited response.” — Seymour Papert, Mindstorms You may not know it, but our ...

Rallybio has swerved away from its Recursion Pharmaceuticals pact, accepting $7.5 million upfront for its share of a preclinical program to extend its cash runway to mid-2027. Exscientia, now part of ...